Bertuccioli Alexander, Sisti Davide, Lazzerini Nadia, Palazzi Chiara Maria, Zonzini Giordano Bruno, Ragazzini Mirko, Belli Annalisa
Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Microbiota International Clinical Society, Torino, Italy.
Front Med (Lausanne). 2025 May 20;12:1604319. doi: 10.3389/fmed.2025.1604319. eCollection 2025.
Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, and altered bowel habits. Probiotic-based strategies are increasingly being explored for IBS management, with growing interest in strain-specific applications.
This study aimed to evaluate the clinical efficacy of CBM588 and W11 in IBS patients with diarrhea-predominant (IBS-D) and constipation-predominant (IBS-C) symptoms, respectively.
A total of 51 IBS patients were recruited and stratified into two groups: IBS-D patients received CBM588 (Butirrisan®), while IBS-C patients received W11 (Bowell®). Symptom severity was assessed using the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) before and after a 3-month intervention. Generalized linear models and regression analyses were used to evaluate treatment effects.
Both probiotic formulations significantly reduced IBS-SSS scores, particularly improving bloating, abdominal pain, and overall quality of life. The impact of treatment was independent of age, though greater improvements in bloating and life interference were observed in older IBS-C patients. A direct correlation between baseline symptom severity and symptom reduction was identified, suggesting higher efficacy in more severe cases.
This study supports the use of CBM588 and W11 as effective probiotic interventions for IBS-D and IBS-C, respectively. Their strain-specific benefits highlight the potential of targeted probiotic strategies in IBS management. Future studies with larger sample sizes and longer follow-up periods are recommended to confirm and expand these findings.
肠易激综合征（IBS）是一种慢性功能性胃肠疾病，其特征为腹痛、腹胀和排便习惯改变等症状。基于益生菌的治疗策略在IBS管理中越来越受到探索，对特定菌株应用的兴趣也日益增加。
本研究旨在分别评估CBM588和W11对腹泻型（IBS-D）和便秘型（IBS-C）IBS患者的临床疗效。
共招募了51名IBS患者，并将其分为两组：IBS-D患者接受CBM588（Butirrisan®），而IBS-C患者接受W11（Bowell®）。在3个月的干预前后，使用肠易激综合征严重程度评分系统（IBS-SSS）评估症状严重程度。采用广义线性模型和回归分析来评估治疗效果。
两种益生菌制剂均显著降低了IBS-SSS评分，尤其改善了腹胀、腹痛和整体生活质量。治疗效果与年龄无关，尽管在老年IBS-C患者中观察到腹胀和生活干扰方面有更大改善。确定了基线症状严重程度与症状减轻之间的直接相关性，表明在更严重的病例中疗效更高。
本研究支持将CBM588和W11分别作为IBS-D和IBS-C的有效益生菌干预措施。它们特定菌株的益处凸显了针对性益生菌策略在IBS管理中的潜力。建议未来进行更大样本量和更长随访期的研究以证实和扩展这些发现。
